1. Home
  2. Clinical Topics
  3. FDA approves first drug for postpartum depression
Clinical TopicsDrugs and DevicesWeb Exclusives

FDA approves first drug for postpartum depression


On March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression. Zulresso will be available only through a restricted program that requires the drug be administered by a healthcare provider in a certified health care facility.

Read more at FDA.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts